Polygenic Score (PGS) ID: PGS000328

Predicted Trait
Reported Trait Systemic lupus erythematosus
Mapped Trait(s) systemic lupus erythematosus (MONDO_0007915)
Released in PGS Catalog: Sept. 18, 2020
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name GRS_SLE
Development Method
Name Genomewide-significant variants (sourced from PMID:28509669)
Parameters p < 5e-8
Variants
Original Genome Build NR
Number of Variants 57
Effect Weight Type log(OR)
PGS Source
PGS Catalog Publication (PGP) ID PGP000099
Citation (link to publication) Reid S et al. Ann Rheum Dis (2019)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
14,267 individuals (100%)
PGS Evaluation
European: 100%
3 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST003155
Europe PMC: 26502338
 14,267 individuals European NR

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM000882 PSS000438|
European Ancestry|
15,383 individuals
 PGP000099 |
Reid S et al. Ann Rheum Dis (2019)
 Reported Trait: Systemic lupus erythematosus — AUROC: 0.71 Odds Ratio (OR; highest vs. lowest quartile): 7.48 [6.73, 8.32] — —
PPM000880 PSS000436|
European Ancestry|
3,803 individuals
 PGP000099 |
Reid S et al. Ann Rheum Dis (2019)
 Reported Trait: Systemic lupus erythematosus — AUROC: 0.78 Odds Ratio (OR; highest vs. lowest quartile): 12.32 [9.53, 15.71] — —
PPM000883 PSS000436|
European Ancestry|
3,803 individuals
 PGP000099 |
Reid S et al. Ann Rheum Dis (2019)
 Reported Trait: Systemic Lupus damage score (SDI) OR: 1.13 [1.03, 1.24] — Odds Ratio (OR; highest vs. lowest quartile): 1.47 [1.06, 2.04] — —
PPM000881 PSS000437|
European Ancestry|
1,001 individuals
 PGP000099 |
Reid S et al. Ann Rheum Dis (2019)
 Reported Trait: Systemic lupus erythematosus (onset before age 20) — AUROC: 0.83 — — —
PPM000885 PSS000437|
European Ancestry|
1,001 individuals
 PGP000099 |
Reid S et al. Ann Rheum Dis (2019)
 Reported Trait: Nephritis in systemic lupus erythematosus patients — — Hazard Ratio (HR; highest vs. lowest quartile): 2.53 [1.72, 3.71] — —
PPM000884 PSS000436|
European Ancestry|
3,803 individuals
 PGP000099 |
Reid S et al. Ann Rheum Dis (2019)
 Reported Trait: Systemic lupus erythematosus (age-at-onset) — — Hazard Ratio (HR; highest vs. lowest quartile): 1.47 [1.22, 1.75] — —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000436 The discovery cohort included 1001 patients from the University clinics in Uppsala, Linköping, Karolinska Institute (Stockholm), Lund, and from the four northern-most counties in Sweden. All subjects fulfilled ≥4 ACR-82 classification criteria for SLE and were of European descent.30 Clinical data were collected from the patients’ medical files, including SDI scores, the ACR-82 classification criteria, clinical antiphospholipid syndrome (APS) diagnosis, glomerular filtration rate, chronic kidney disease (CKD) stages, ESRD, renal biopsy data and CVE, defined as myocardial infarction, ischaemic cerebrovascular disease or venous thromboembolism (VTE). Control individuals were healthy blood donors from Uppsala (Uppsala Bioresource) and Lund or population based controls from Stockholm and the four northernmost counties of Sweden. —
[
  • 1,001 cases
  • , 2,802 controls
]
 — European — Karolinska, UHU The discovery cohort included 1001 patients from the University clinics in Uppsala, Linköping, Karolinska Institute (Stockholm), Lund, and from the four northern-most counties in Sweden
PSS000437 The discovery cohort included 1001 patients from the University clinics in Uppsala, Linköping, Karolinska Institute (Stockholm), Lund, and from the four northern-most counties in Sweden. All subjects fulfilled ≥4 ACR-82 classification criteria for SLE and were of European descent.30 Clinical data were collected from the patients’ medical files, including SDI scores, the ACR-82 classification criteria, clinical antiphospholipid syndrome (APS) diagnosis, glomerular filtration rate, chronic kidney disease (CKD) stages, ESRD, renal biopsy data and CVE, defined as myocardial infarction, ischaemic cerebrovascular disease or venous thromboembolism (VTE). —
[
  • 1,001 cases
  • , 0 controls
]
 — European — Karolinska, UHU The discovery cohort included 1001 patients from the University clinics in Uppsala, Linköping, Karolinska Institute (Stockholm), Lund, and from the four northern-most counties in Sweden
PSS000438 — —
[
  • 5,524 cases
  • , 9,859 controls
]
 — European — NR The replication cohort is described in Langefeld et al. (PMID:28714469)